Table 23.15 Cancer of the Prostate (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2016 By Race/Ethnicity and Years Since Diagnosis

| Years Since Diagnosis | 0 to <5 | 5 to <10 | 10 to <15 | 15 to <20 | 20 to <24 | 0 to <24 ^b | >=24 ^d | Complete ^e |
|------------------------|---------|----------|-----------|-----------|-----------|-----------------------|-------------------|-----------------------|
| Race All Races | 925,846 | 945,574 | 660,380 | 387,565 | 150,033 | 3,069,398 | 41,006 | 3,110,403 |
| White | 724,023 | 764,898 | 550,849 | 327,374 | 129,883 | 2,497,026 | 44,331 | 2,628,705 |
| Black | 138,607 | 128,648 | 83,217 | 46,936 | 16,450 | 413,858 | 4,779 | 418,637 |
| Asian/Pacific Islander | 21,563 | 19,811 | 12,673 | 5,940 | 1,897 | 61,883 | + | + |
| Hispanic | 60,114 | 54,746 | 36,830 | 17,966 | 6,233 | 175,889 | + | + |

Estimated prevalence percent^a on January 1, 2016, of the SEER population diagnosed in the previous 24 years By Age at Prevalence and Race/Ethnicity

| | Age Specific (Crude) | | | | | | | | Age-Adjusted ^c | | |
|--------------------------|----------------------|--------|--------|--------|--------|--------|--------|--------|---------------------------|---------|----------|
| Age at Prevalence | All Ages | 0-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60-69 | 70-79 | 80+ | All Ages |
| <u>Race</u> All Races | 1.9347 | 0.0001 | 0.0002 | 0.0002 | 0.0010 | 0.0692 | 1.0107 | 5.0637 | 12.8866 | 17.5576 | 1.8440 |
| White | 1.9984 | 0.0002 | 0.0003 | 0.0003 | 0.0008 | 0.0538 | 0.8859 | 4.7049 | 12.3728 | 17.0503 | 1.7533 |
| Black | 1.9131 | - | = | 0.0002 | 0.0021 | 0.1784 | 1.9464 | 8.3071 | 18.4946 | 22.5283 | 2.7086 |
| Asian/Pacific Islander | 0.6344 | - | - | - | - | 0.0130 | 0.2989 | 1.9809 | 5.7864 | 9.5868 | 0.8474 |
| Hispanic | 0.6095 | 0.0002 | 0.0002 | 0.0001 | 0.0006 | 0.0334 | 0.5553 | 3.2066 | 9.3286 | 13.5466 | 1.3218 |

US 2016 cancer prevalence counts are based on 2016 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2016 US population estimates based on the average of 2015 and 2016 population estimates from the US Bureau of the Census. а

b

Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 24 years. Maximum limited-duration prevalence is 24 years for 1992-2016 data.

Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. Cases diagnosed more than 24 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Complete prevalence is obtained by summing 0 to <24 and >=24.

Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

Not available.